Skip to content

Depression research published in 2025

Page 38 of 39: studies 741 to 760 of 761, newest first. Back to the depression overview

Studies

Is there a risk of addiction to ketamine during the treatment of depression? A systematic review of available literature.

Journal of Psychopharmacology 2025 Gianmarco Ingrosso, Anthony J. Cleare, Mario F Juruena 20 citations

Ketamine has demonstrated both rapid and sustained efficacy in treating depression, especially in treatment-resistant cases. However, concerns regarding the addictive potential of ketamine during long-term depression treatment persist among clinicians. This review aimed to summarise the evidence on addiction phenomena associated with ketamine treatment of depression. A comprehensive search was...

Impact of social determinants of health on esketamine nasal spray initiation among patients with treatment-resistant depression in the United States.

Journal of managed care & specialty pharmacy 2025 Kristin Clemens, Maryia Zhdanava, Amanda Teeple et al. 4 citations

Disparities in mental health care access and health outcomes based on sociodemographic factors in the United States have been extensively documented. However, there is limited knowledge regarding these socioeconomic factors with respect to initiation of esketamine nasal spray, a novel therapy for treatment-resistant depression (TRD). To evaluate the association of socioeconomic factors with the...

DOI: 10.18553/jmcp.2025.24240 (opens in new tab) Full text (opens in new tab) Mental health Healthcare disparities Depression treatment Socioeconomic status +1

Characterizing the therapeutical use of ketamine for adolescent rats of both sexes: Antidepressant-like efficacy and safety profile.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2025 Jordi Jornet-Plaza, Sandra Ledesma-Corvi, M Julia García-Fuster 6 citations

While ketamine was approved for treatment-resistant depression in adult patients, its efficacy and safety profile for adolescence still requires further characterization. In this context, prior preclinical studies have shown that sub-anesthetic doses of ketamine during adolescence exert antidepressant-like effects in rodents in a dose- and sex-dependent manner. However, additional studies...

MDMA and MDMA-Assisted Therapy.

American Journal of Psychiatry 2025 Aaron Wolfgang, Gregory A. Fonzo, Joshua C. Gray et al. 47 citations

MDMA (i.e., 3,4-methylenedixoymethamphetamine), commonly known as "Ecstasy" or "Molly," has been used since the 1970s both in recreational and therapeutic settings. The Food and Drug Administration (FDA) designated MDMA-Assisted Therapy (MDMA-AT) as a Breakthrough Therapy for posttraumatic stress disorder (PTSD) in 2017, and the FDA is requiring an additional phase 3 trial after rejecting the...

Esketamine Treatment Trajectory of Patients with Treatment-Resistant Depression in the Mid and Long-Term Run: Data from REAL-ESK Study Group.

Current Neuropharmacology 2025 Gianluca Rosso, Giacomo d'Andrea, Stefano Barlati et al. 23 citations

Data on long-term treatment with Esketamine Nasal Spray (ESKNS) in real-world patients with treatment resistant depression (TRD) is scarce. The primary aim of the study is to evaluate the effectiveness and tolerability of ESK-NS treatment at 6 and 12-month follow-ups. This is part of an observational, retrospective, multicentric Italian study (REAL-ESK study). Subjects for the present study...

Is there a risk of esketamine misuse in clinical practice?

Therapeutic advances in drug safety 2025 Carlos Roncero, Milton Merizalde-Torres, Néstor Szerman et al. 11 citations

In 2019, intranasal esketamine gained approval as a promising therapy for those individuals grappling with treatment-resistant depression. Both clinical trials and real-world studies have underscored its efficacy in alleviating and remitting depressive symptoms, with sustained benefits observed for nearly 4.5 years. As the S-enantiomer of ketamine, esketamine's dosing guidelines and strict...

Trends in research on novel antidepressant treatments.

Frontiers in Pharmacology 2025 Agnieszka Zelek-Molik, Ewa Litwa 19 citations

Mood disorders, such as major depressive disorder and bipolar disorder, are among the most common mental illnesses and a leading cause of disability worldwide. Key symptoms of these conditions include a depressed mood or anhedonia, sleep and psychomotor disturbances, changes in appetite or weight, and fatigue or loss of energy. Prolonged cognitive disturbances further impair the ability to...

Ketamine effects on resting state functional brain connectivity in major depressive disorder patients: a hypothesis-driven analysis based on a network model of depression.

Frontiers in Neuroscience 2025 Kasper Recourt, Joop van Gerven, Nadieh Drenth et al. 1 citation

Ketamine demonstrates robust and rapidly occurring antidepressant effects in patients with difficult-to-treat major depressive disorder. Ketamine's antidepressant effects and its impact on functional networks in non-resistant forms of major depressive disorder are expected to provide valuable insight into ketamine's mechanism of action related to depression. This study employs an existing...

Body mass index is associated with the antidepressant effects of intravenous ketamine in patients with depression.

Frontiers in Psychiatry 2025 Jian-Qiang Tan, Li-Mei Gu, Yan-Ling Zhou et al. 2 citations

We aimed to explore the correlation between baseline body mass index (BMI) and the antidepressant properties of intravenous ketamine in patients with depression. We divided 135 patients diagnosed with either major depressive disorder (n=103) or bipolar depression (n=32) into lower and higher BMI groups based on their baseline BMI. Patients with a lower BMI (BMI0.05). The linear mixed models...

Music mindfulness acutely modulates autonomic activity and improves psychological state in anxiety and depression.

Frontiers in Neuroscience 2025 Christine Ramirez, Gertrude Asumpaame Alayine, Cyril Selase Kwaku Akafia et al. 3 citations

Anxiety and depression reduce autonomic system activity, as measured by Heart Rate Variability (HRV), and exacerbate cardiac morbidity. Both music and mindfulness have been shown to increase HRV, and clinical approaches incorporating these interventions show promise as effective treatments for symptoms of anxiety and depression. Music mindfulness, which combines music listening with mindfulness...

How do inner screens enable imaginative experience? Applying the free-energy principle directly to the study of conscious experience.

Neuroscience of Consciousness 2025 Chris Fields, Mahault Albarracin, Karl Friston et al. 6 citations

This paper examines the constraints that the free-energy principle (FEP) places on possible model of consciousness, particularly models of attentional control and imaginative experiences, including episodic memory and planning. We first rehearse the classical and quantum formulations of the FEP, focusing on their application to multi-component systems, in which only some components interact...

DOI: 10.1093/nc/niaf009 (opens in new tab) Full text (opens in new tab) Depression Aphantasia Cognitive architecture Inner speech +13

Ascorbic Acid and Esketamine for Mental Disorders in Women with Miscarriage: A Randomized Controlled Double-Blind Trial Protocol.

Neuropsychiatric Disease and Treatment 2025 Zhaojuan Ke, Ying Zhang, Binyang Cai et al. 1 citation

Pregnancy leads to vulnerabilities and susceptibilities to mental disorders. Miscarriage, as an adverse pregnancy outcome, and following curettage for treatment, add the risks of further psychiatric disorders, including depression, anxiety, insomnia, etc., and current approaches to prevention are unsatisfactory. Ketamine and its S-enantiomer esketamine can prevent postpartum depression, and...

Case Report: Successful management of psychogenic non-epileptic seizures with intranasal esketamine.

Frontiers in Psychiatry 2025 Muneeb Hashmi, Padmasini Mugunthan, Priyal Jain et al. 2 citations

Psychogenic non-epileptic seizures (PNES), or functional seizures (FS), are episodes that resemble epileptic seizures but may be psychological in origin. Unlike epileptic seizures, which are linked to abnormal electrical activity in the brain, functional seizures may be associated with psychological and/or physical distress, and do not show the same electrical patterns on an...

Lateral habenula astroglia modulate the potentiating antidepressant-like effects of bright light stimulation in intractable depression.

Frontiers in Pharmacology 2025 Sarah Delcourte, Amel Bouloufa, Renaud Rovera et al. 3 citations

Beside image vision, light plays a pivotal role in regulating diverse non-visual functions, including affective behaviors. Recently, bright light stimulation (BLS) was revealed to be beneficial for treating non-seasonal depression, although its mechanism of action is not fully understood. We developed a novel mouse model of refractory depression, induced through social isolation and chronic...

Unveiling the Psychedelic Journey: An Appraisal of Psilocybin as a Profound Antidepressant Therapy.

Molecular biotechnology 2025 Fatima Iftikhar Shah, Somia Shehzadi, Fatima Akram et al. 2 citations

Depression, a global health concern with significant implications for suicide rates, remains challenging to treat effectively with conventional pharmacological options. The existing pharmaceutical interventions for these illnesses need daily dosing, are accompanied by various adverse effects, and may exhibit limited efficacy in certain cases. However, hope emerges from an unlikely...

DOI: 10.1007/s12033-023-00994-7 (opens in new tab) Full text (opens in new tab) Disorder Mushroom Psilocybin therapy Mental health treatment +3

Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression

American Journal of Psychiatry 2025 Johannes G. Ramaekers, Johannes T. Reckweg, Natasha L. Mason 25 citations

Unlike classical antidepressants, psychedelics such as psilocybin have been shown to induce a rapid antidepressant response. In the wake of this development, interest has emerged in ultra-fast, short-acting psychedelics such as 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and N,N-dimethyltryptamine (DMT) with the expectation that these can produce rapid antidepressant effects following an...

DOI: 10.1176/appi.ajp.20230890 (opens in new tab) 5-MEO-DMT Depression Psychedelic drugs Quick-onset treatment +3

Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial

American Journal of Psychiatry 2025 Scott T Aaronson, Andrew van der Vaart, Tammy Miller et al. 31 citations

This open-label study suggests efficacy and safety of psilocybin in severe TRD and supports further study of psychedelics in this population, including consideration of PTSD interaction effects.

Psilocybin-Assisted Group Psychotherapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider COVID-19 Related Depression and Burnout: A Randomized Clinical Trial

medRxiv 2025 Benjamin R. Lewis, John Hendrick, Kevin Byrne et al. 3 citations preprint

Abstract Objective This clinical trial sought to evaluate the safety and preliminary efficacy of psilocybin and MBSR for frontline healthcare providers with symptoms of depression and burnout related to the COVID-19 pandemic. Methods This was a randomized controlled trial that enrolled physicians and nurses with frontline clinical work during the COVID-19 pandemic and symptoms of depression and...

Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity.

Neuropsychiatric Disease and Treatment 2025 Daniel A Kinderlehrer 13 citations

The incidence of mental health disorders is increasing worldwide. While there are multiple factors contributing to this problem, neuroinflammation underlies a significant subset of psychiatric conditions, particularly major depressive and anxiety disorders. Anti-inflammatory interventions have demonstrated benefit in these conditions. Psilocin, the active ingredient of mushrooms in the...

Ayahuasca partially preserves striatal integrity in juvenile non-human primates exposed to chronic stress: evidence from stereological evaluation.

Frontiers in Neuroanatomy 2025 Wigínio Gabriel de Lira-Bandeira, Lílian Andrade Carlos de Mendonça Batista, Andréa Silva de Medeiros Bandeira et al. 4 citations

The striatum (St) integrates cognitive, motor, and limbic functions and plays a critical role in processing emotions, motivation, and rewards. It may undergo several morphophysiological changes in neuropsychiatric diseases. Depression, a complex psychiatric disorder, affects millions of people around the world and leads to an increased risk of suicide, decreased quality of life, and functional...